奎奴普丁-达福普汀对革兰氏阳性和阴性菌的抗生素后效应及抗生素后亚抑菌浓度效应
Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms.
作者信息
Pankuch G A, Jacobs M R, Appelbaum P C
机构信息
Departments of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033, USA.
出版信息
Antimicrob Agents Chemother. 1998 Nov;42(11):3028-31. doi: 10.1128/AAC.42.11.3028.
Abstract
Quinupristin-dalfopristin produced postantibiotic effects (PAEs) and postantibiotic sub-MIC effects of >2 h against 18 gram-positive cocci. Mean pneumococcal and staphylococcal PAEs were 2.8 and 4.7 h, respectively, with shorter PAEs for constitutively than inducibly macrolide-resistant staphylococci. Mean PAEs for vancomycin-susceptible and -resistant Enterococcus faecium were 8.5 and 2.6 h, respectively.
摘要
奎奴普丁-达福普汀对18株革兰氏阳性球菌产生了抗生素后效应（PAEs）以及大于2小时的抗生素后亚抑菌浓度效应。肺炎球菌和葡萄球菌的平均PAEs分别为2.8小时和4.7小时，组成型大环内酯耐药葡萄球菌的PAEs比诱导型的短。万古霉素敏感和耐药的粪肠球菌的平均PAEs分别为8.5小时和2.6小时。
相似文献
1
Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms.奎奴普丁-达福普汀对革兰氏阳性和阴性菌的抗生素后效应及抗生素后亚抑菌浓度效应
Antimicrob Agents Chemother. 1998 Nov;42(11):3028-31. doi: 10.1128/AAC.42.11.3028.
2
In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.奎奴普丁/达福普汀的体外和体内抗菌活性。
J Antimicrob Chemother. 1997 May;39 Suppl A:15-21. doi: 10.1093/jac/39.suppl_1.15.
3
In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).奎奴普丁/达福普汀（Synercid）的体外活性及抗生素后效应
Chemotherapy. 2001 Jul-Aug;47(4):243-9. doi: 10.1159/000048530.
4
Quinupristin-dalfopristin.奎奴普丁-达福普汀
Drugs. 1996 Sep;52(3):406-15. doi: 10.2165/00003495-199652030-00006.
5
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.对从美国和加拿大200个医疗中心收集的28000多株近期临床分离菌进行了奎奴普丁-达福普汀（RP 59500，Synercid）的抗菌活性测试。
Diagn Microbiol Infect Dis. 1998 Jul;31(3):437-51. doi: 10.1016/s0732-8893(98)80002-3.
6
Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.奎奴普丁/达福普汀的抗菌活性。临床应用原理。
Drugs. 1996;51 Suppl 1:31-7. doi: 10.2165/00003495-199600511-00007.
7
Postantibiotic effect of tigecycline against 14 gram-positive organisms.替加环素对14种革兰氏阳性菌的抗生素后效应。
Antimicrob Agents Chemother. 2009 Feb;53(2):782-4. doi: 10.1128/AAC.01122-08. Epub 2008 Dec 8.
8
Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum.喹奴普丁/达福普汀的抗菌活性，一种新型的具有广泛革兰氏阳性菌谱的注射用链阳菌素。
Int J Antimicrob Agents. 1999 Sep;13(1):21-8. doi: 10.1016/s0924-8579(99)00092-8.
9
Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.达托霉素、利奈唑胺和奎奴普丁/达福普汀对某大型癌症中心革兰氏阳性菌分离株的体外活性比较
Diagn Microbiol Infect Dis. 2005 Jul;52(3):255-9. doi: 10.1016/j.diagmicrobio.2005.02.015.
10
Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.针对来自拉丁美洲的革兰氏阳性球菌检测的奎奴普丁/达福普汀的抗菌药敏性：全球SMART（GSMART）监测研究结果
Braz J Infect Dis. 2001 Feb;5(1):21-31. doi: 10.1590/s1413-86702001000100004.
引用本文的文献
1
Molecular Mechanisms of Drug Resistance in .肿瘤多药耐药相关基因的分子机制研究进展
Int J Mol Sci. 2022 Jul 22;23(15):8088. doi: 10.3390/ijms23158088.
2
Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin against Klebsiella pneumoniae in a Neutropenic Murine Lung Infection Model.安妥沙星在中性粒细胞减少小鼠肺部感染模型中对肺炎克雷伯菌的药代动力学和药效学特征
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02691-16. Print 2017 May.
3
In Vivo Pharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of Streptococcus suis Serotype 2 at Varied Initial Inoculum Sizes.在不同初始接种量的猪链球菌2型中性粒细胞减少小鼠大腿模型中头孢喹肟的体内药效学研究
Antimicrob Agents Chemother. 2015 Dec 14;60(2):1114-20. doi: 10.1128/AAC.02065-15. Print 2016 Feb.
4
Manuka-type honeys can eradicate biofilms produced by Staphylococcus aureus strains with different biofilm-forming abilities.麦卢卡蜂蜜可以消除不同生物膜形成能力的金黄色葡萄球菌菌株产生的生物膜。
PeerJ. 2014 Mar 25;2:e326. doi: 10.7717/peerj.326. eCollection 2014.
5
Quinupristin/dalfopristin: the first available macrolide-lincosamide-streptogramin antibiotic.奎奴普丁/达福普汀：第一种可获得的大环内酯-林可酰胺-链阳菌素类抗生素。
Proc (Bayl Univ Med Cent). 2000 Jan;13(1):83-6. doi: 10.1080/08998280.2000.11927646.
6
Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.死菌不会变异：细菌耐药性产生中的易感性问题。
Emerg Infect Dis. 2003 Jan;9(1):10-6. doi: 10.3201/eid0901.020172.
7
Treatment options for vancomycin-resistant enterococcal infections.耐万古霉素肠球菌感染的治疗选择。
Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002.
8
Quinupristin-Dalfopristin.奎奴普丁-达福普汀
Curr Infect Dis Rep. 1999 Dec;1(5):480-487. doi: 10.1007/s11908-999-0062-y.
9
Pronounced postantibiotic effect of quinupristin-dalfopristin in static cultures of Staphylococcus aureus: an effect not seen with other antibiotics.奎奴普丁-达福普汀在金黄色葡萄球菌静态培养物中具有显著的抗生素后效应：其他抗生素未见此效应。
Antimicrob Agents Chemother. 2000 Apr;44(4):1059-61. doi: 10.1128/AAC.44.4.1059-1061.2000.
10
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.奎奴普丁/达福普汀：用于治疗严重革兰氏阳性菌感染的综述
Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008.
本文引用的文献
1
Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.曲伐沙星对革兰氏阳性和阴性菌的抗生素后效应
Antimicrob Agents Chemother. 1998 Jun;42(6):1503-5. doi: 10.1128/AAC.42.6.1503.
2
The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans.奎奴普丁/达福普汀在实验动物和人类中的药代动力学。
J Antimicrob Chemother. 1997 May;39 Suppl A:129-38. doi: 10.1093/jac/39.suppl_1.129.
3
Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.喹奴普丁/达福普汀对肠球菌属的体外活性比较
J Antimicrob Chemother. 1997 May;39 Suppl A:41-6. doi: 10.1093/jac/39.suppl_1.41.
4
Distribution of genes encoding resistance to streptogramin A and related compounds among staphylococci resistant to these antibiotics.对链阳菌素A及相关化合物耐药的葡萄球菌中编码对这些抗生素耐药性的基因分布情况。
Antimicrob Agents Chemother. 1996 Nov;40(11):2523-8. doi: 10.1128/AAC.40.11.2523.
5
Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies.采用最低抑菌浓度（MIC）和快速杀菌方法测定RP 59500（奎奴普丁-达福普汀）、青霉素G、红霉素和司帕沙星的抗肺炎球菌活性。
Antimicrob Agents Chemother. 1996 Jul;40(7):1653-6. doi: 10.1128/AAC.40.7.1653.
6
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.注射用链阳性菌素类抗生素RP59500对耐万古霉素革兰氏阳性菌的体外活性
Antimicrob Agents Chemother. 1993 Mar;37(3):598-601. doi: 10.1128/AAC.37.3.598.
7
Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.美罗培南的抗生素后效应及抗生素后亚抑菌浓度效应研究。
J Antimicrob Chemother. 1993 Jun;31(6):881-92. doi: 10.1093/jac/31.6.881.
8
The postantibiotic effect of RP 59500 on Staphylococcus aureus including strains with a raised MBC.RP 59500对金黄色葡萄球菌包括具有升高的最低杀菌浓度（MBC）的菌株的抗生素后效应。
J Antimicrob Chemother. 1994 Jun;33(6):1219-22. doi: 10.1093/jac/33.6.1219.
9
Kinetics of antimicrobial activity.
J Pediatr. 1986 May;108(5 Pt 2):835-40. doi: 10.1016/s0022-3476(86)80754-5.
10
Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification.细菌通过靶点修饰对大环内酯类、林可酰胺类和链阳菌素类抗生素产生耐药性。
Antimicrob Agents Chemother. 1991 Jul;35(7):1267-72. doi: 10.1128/AAC.35.7.1267.
Zotero 插件